D-Index & Metrics Best Publications

Paul S. Aisen

University of Southern California
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 114 Citations 64,992 583 World Ranking 2674 National Ranking 1542

Overview

What is he best known for?

The fields of study he is best known for:

Internal medicine
Alzheimer's disease
Disease

His primary areas of study are Alzheimer's disease, Internal medicine, Disease, Dementia and Clinical trial. The various areas that Paul S. Aisen examines in his Alzheimer's disease study include Biomarker, Neuroimaging and Degenerative disease. His Internal medicine research is multidisciplinary, incorporating perspectives in Placebo, Oncology and Endocrinology.

His biological study spans a wide range of topics, including Gerontology, Bioinformatics, Intensive care medicine, Pathophysiology and Neuroscience. His Dementia study combines topics in areas such as Meta-analysis, Psychiatry, Central nervous system disease and Pediatrics. As a part of the same scientific family, he mostly works in the field of Alzheimer's Disease Neuroimaging Initiative, focusing on Alzheimer's disease biomarkers and, on occasion, Senile plaques and Neurodegeneration.

His most cited work include:

Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (4114 citations)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2965 citations)
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. (2323 citations)

What are the main themes of his work throughout his whole career to date?

Disease, Alzheimer's disease, Internal medicine, Clinical trial and Dementia are his primary areas of study. His studies in Disease integrate themes in fields like Gerontology, Neuroimaging, Cognition, Neuroscience and Biomarker. His Cognition research includes elements of Cohort and Clinical psychology.

Specifically, his work in Alzheimer's disease is concerned with the study of Alzheimer's Disease Neuroimaging Initiative. Paul S. Aisen has researched Internal medicine in several fields, including Placebo, Oncology and Endocrinology. His Clinical trial research integrates issues from Physical medicine and rehabilitation, Drug development, Intensive care medicine, Physical therapy and Neurology.

He most often published in these fields:

Disease (38.75%)
Alzheimer's disease (32.83%)
Internal medicine (32.49%)

What were the highlights of his more recent work (between 2017-2021)?

Disease (38.75%)
Clinical trial (23.69%)
Internal medicine (32.49%)

In recent papers he was focusing on the following fields of study:

Paul S. Aisen mostly deals with Disease, Clinical trial, Internal medicine, Cognition and Dementia. His Disease study incorporates themes from Neurology, Drug development, Asymptomatic and Intensive care medicine. The concepts of his Clinical trial study are interwoven with issues in Biomarker, Geriatrics gerontology, Physical medicine and rehabilitation and Observational study.

His Internal medicine study integrates concerns from other disciplines, such as Placebo and Oncology. His Dementia research incorporates elements of Randomized controlled trial, Neuroscience, Verubecestat and Pediatrics. Paul S. Aisen has included themes like MEDLINE and Cognitive test in his Alzheimer's disease study.

Between 2017 and 2021, his most popular works were:

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease (273 citations)
Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease (179 citations)
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative (100 citations)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Reisa A. Sperling;Paul S. Aisen;Laurel A. Beckett;David A. Bennett.
Alzheimers & Dementia (2011)

4881 Citations

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Clifford R Jack;David S Knopman;William J Jagust;Leslie M Shaw.
Lancet Neurology (2010)

4400 Citations

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Clifford R Jack;David S Knopman;William J Jagust;Ronald C Petersen.
Lancet Neurology (2013)

3424 Citations

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease

Randall J. Bateman;Chengjie Xiong;Tammie L.S. Benzinger;Anne M. Fagan.
The New England Journal of Medicine (2012)

3239 Citations

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Leslie M. Shaw;Hugo Vanderstichele;Malgorzata Knapik-Czajka;Christopher M. Clark.
Annals of Neurology (2009)

2030 Citations

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

RS Rachelle S. Doody;RG Ronald G. Rg Thomas;Martin Farlow;Takeshi Iwatsubo.
The New England Journal of Medicine (2014)

1487 Citations

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Michael W. Weiner;Michael W. Weiner;Dallas P. Veitch;Paul S. Aisen;Laurel A Beckett.
Alzheimers & Dementia (2012)

1233 Citations

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

Bruno Dubois;Harald Hampel;Harald Hampel;Howard H. Feldman;Philip Scheltens.
Alzheimers & Dementia (2016)

1218 Citations

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

R. C. Petersen;P. S. Aisen;Laurel A Beckett;M. C. Donohue.
Neurology (2010)

1206 Citations

Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.

Michael Grundman;Ronald C. Petersen;Steven H. Ferris;Ronald G. Thomas.
JAMA Neurology (2004)

1136 Citations

If you think any of the details on this page are incorrect, let us know.

Frequent Co-Authors

External Links

Personal Website for Paul S. Aisen